173 related articles for article (PubMed ID: 16133789)
1. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Hartmann JT; Oechsle K; Huober J; Jakob A; Azemar M; Horger M; Kanz L; Bokemeyer C
Invest New Drugs; 2006 May; 24(3):249-53. PubMed ID: 16133789
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Ferraresi V; Ciccarese M; Cercato MC; Nuzzo C; Zeuli M; Di Filippo F; Giannarelli D; Cognetti F
Cancer Chemother Pharmacol; 2008 Dec; 63(1):149-55. PubMed ID: 18351342
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Patel SR; Gandhi V; Jenkins J; Papadopolous N; Burgess MA; Plager C; Plunkett W; Benjamin RS
J Clin Oncol; 2001 Aug; 19(15):3483-9. PubMed ID: 11481354
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
8. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
11. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].
Amodio A; Carpano S; Manfredi C; Del Monte G; Di Lauro L; Gionfra T; Conti F; Paoletti G; Lopez M
Clin Ter; 1999; 150(1):17-20. PubMed ID: 10367540
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Cojocaru E; Thway K; Fisher C; Messiou C; Zaidi S; Miah AB; Benson C; Gennatas S; Huang P; Jones RL
Anticancer Res; 2020 Dec; 40(12):7003-7007. PubMed ID: 33288595
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Dileo P; Morgan JA; Zahrieh D; Desai J; Salesi JM; Harmon DC; Quigley MT; Polson K; Demetri GD; George S
Cancer; 2007 May; 109(9):1863-9. PubMed ID: 17385194
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Svancárová L; Blay JY; Judson IR; van Hoesel QG; van Oosterom AT; le Cesne A; Keizer HJ; Hermans C; van Glabbeke M; Verweij J; Hogendoorn PC; Nielsen OS
Eur J Cancer; 2002 Mar; 38(4):556-9. PubMed ID: 11872349
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X
Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
